Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma

PURPOSE: Adequately prioritizing the numerous therapies and biomarkers available in late-stage testing for patients with glioblastoma (GBM) requires an efficient clinical testing platform. We developed and implemented INSIGhT (Individualized Screening Trial of Innovative Glioblastoma Therapy) as a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, Brian M., Trippa, Lorenzo, Gaffey, Sarah, Arrillaga-Romany, Isabel C., Lee, Eudocia Q., Rinne, Mikael L., Ahluwalia, Manmeet S., Colman, Howard, Fell, Geoffrey, Galanis, Evanthia, de Groot, John, Drappatz, Jan, Lassman, Andrew B., Meredith, David M., Nabors, L. Burt, Santagata, Sandro, Schiff, David, Welch, Mary R., Ligon, Keith L., Wen, Patrick Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448806/
https://www.ncbi.nlm.nih.gov/pubmed/32914038
http://dx.doi.org/10.1200/PO.18.00071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448806/
https://www.ncbi.nlm.nih.gov/pubmed/32914038
http://dx.doi.org/10.1200/PO.18.00071

Ejemplares similares